Natixis Advisors LLC Acquires 11,210 Shares of Insulet Co. (NASDAQ:PODD)

Natixis Advisors LLC grew its position in Insulet Co. (NASDAQ:PODD - Free Report) by 33.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,371 shares of the medical instruments supplier's stock after acquiring an additional 11,210 shares during the period. Natixis Advisors LLC owned about 0.06% of Insulet worth $11,584,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Baillie Gifford & Co. raised its position in Insulet by 3.5% during the fourth quarter. Baillie Gifford & Co. now owns 2,355,683 shares of the medical instruments supplier's stock worth $614,998,000 after acquiring an additional 79,982 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Insulet by 1.3% in the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock valued at $403,339,000 after buying an additional 22,850 shares during the last quarter. Westfield Capital Management Co. LP raised its position in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock valued at $175,697,000 after buying an additional 163,388 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Insulet by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 646,959 shares of the medical instruments supplier's stock valued at $168,902,000 after buying an additional 10,694 shares during the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Insulet by 7.6% in the fourth quarter. Fisher Asset Management LLC now owns 377,694 shares of the medical instruments supplier's stock valued at $98,605,000 after buying an additional 26,594 shares during the last quarter.

Remove Ads

Insulet Stock Performance

Shares of PODD stock traded up $1.49 during trading hours on Friday, reaching $266.88. The stock had a trading volume of 652,346 shares, compared to its average volume of 686,563. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The firm has a 50-day simple moving average of $272.11 and a 200-day simple moving average of $256.26. The firm has a market capitalization of $18.74 billion, a PE ratio of 46.26, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. The firm had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. As a group, equities analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on PODD shares. StockNews.com lowered shares of Insulet from a "buy" rating to a "hold" rating in a research report on Tuesday, March 4th. Royal Bank of Canada started coverage on shares of Insulet in a research note on Thursday, March 6th. They set an "outperform" rating and a $340.00 price objective for the company. Piper Sandler boosted their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Canaccord Genuity Group boosted their price objective on shares of Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Finally, Citigroup upped their target price on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average price target of $292.06.

Insider Activity at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 0.47% of the stock is currently owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.